Till Örebro universitet

oru.seÖrebro universitets publikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Blood Transcriptome Analysis Reveals Enhanced B Cell and Complement Cascade Signatures in Patients with Major Neuropsychiatric Systemic Lupus Erythematosus
Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden.
National and Kapodistrian University of Athens, Athens, Greece.
National and Kapodistrian University of Athens, Athens, Greece.
Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany, Erlangen, Germany.
Visa övriga samt affilieringar
2024 (Engelska)Ingår i: Arthritis & Rheumatology, ISSN 2326-5191, E-ISSN 2326-5205, Vol. 76, nr Suppl. 9, s. 4909-4910, artikel-id 2420Artikel i tidskrift, Meeting abstract (Övrigt vetenskapligt) Published
Abstract [en]

Background/Purpose: The molecular basis of neuropsychiatric systemic lupus erythematosus (NPSLE) remains elusive because of clinical heterogenicity, the complexity of pathophysiologic mechanisms involved and limited access to tissue.

Methods: We performed whole-blood RNA sequencing from 308 SLE [119 with at least one major neuropsychiatric event treated intensive immunosuppressive therapy (NPSLE) and 189 SLE patients with no history of NPSLE (non-NPSLE)] and matched 72 healthy controls (HC). Pathway enrichment analysis, unsupervised weighted gene co-expression network analysis (WGCNA) and deconvolution were applied to reveal NPSLE-specific signatures and distinguish NPSLE endotypes.

Results: Comparison between NPSLE and HC revealed 1292 differentially expressed genes, indicating dysregulation of adaptive immune response, immunoglobulin mediated immune response and classical autoantibody-mediated complement activation along with upregulation of IL-1, IL-6, IL-17, and IL-12/IL-23 signaling. Monocyte, memory B cell and activated memory CD4 T cell proportions were significantly increased in NPSLE compared to HC. The comparison between NPSLE and non-NPSLE revealed a robust upregulation of immunoglobulin complex, complement cascade, DNA damage response (DDR), B cell signatures coupled with increased IL-1 and IL-6 signaling. More importantly, upregulation of B cell and complement activation were more pronounced in active NPSLE compared to inactive NPSLE. Next, we performed unsupervised analysis of SLE transcriptome identifying 16 gene modules of co-expressed genes. Within NPSLE, diffuse NPSLE positively correlated with “oxidative phosphorylation” module. Active NPSLE was characterized by enhanced activity of “autophagy” module compared to inactive NPSLE, while NPSLE with distinct aPL profiles were not associated with specific signatures. Finally, we explored whether specific NPSLE manifestations are associated with distinct transcriptomic signatures. “DDR” and “DNA metabolism” modules correlated with seizures, while the later correlated with acute confusional state. Psychosis was positively associated with the “Inflammation” module. The “Innate immunity” module was positively linked to impaired cognition and the “Chromatin organization” was associated with both impaired cognition and myelitis. Moreover, the “Protein metabolism” was negatively associated with impaired cognition and peripheral neuropathies, while the “Interferon” module significantly correlated with optic neuritis.

Conclusion: Our findings demonstrate that the clinical heterogeneity of NPSLE is mirrored by molecular diversity, with each NPSLE endotype characterized by distinct molecular signatures. Upregulation of the adaptive immune response and com-plement activation is strongly associated with neuropsychiatric involvement in SLE. This suggests that inhibitors of the complement cascade, such as avacopan, and B cell-targeted therapies, like CD19 CAR T cell therapy—which may counteract the transcriptomic abnormalities in NPSLE—have been tested for the treatment of autoimmune diseases and could be further explored for major NPSLE.

Ort, förlag, år, upplaga, sidor
John Wiley & Sons, 2024. Vol. 76, nr Suppl. 9, s. 4909-4910, artikel-id 2420
Nationell ämneskategori
Klinisk medicin
Identifikatorer
URN: urn:nbn:se:oru:diva-118125ISI: 001331419107192OAI: oai:DiVA.org:oru-118125DiVA, id: diva2:1925321
Konferens
ACR Convergence 2024, Washington, D.C., USA, November 14-19, 2024
Tillgänglig från: 2025-01-08 Skapad: 2025-01-08 Senast uppdaterad: 2025-02-18Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Person

Parodis, Ioannis

Sök vidare i DiVA

Av författaren/redaktören
Parodis, Ioannis
Av organisationen
Institutionen för medicinska vetenskaperRegion Örebro län
I samma tidskrift
Arthritis & Rheumatology
Klinisk medicin

Sök vidare utanför DiVA

GoogleGoogle Scholar

urn-nbn

Altmetricpoäng

urn-nbn
Totalt: 97 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf